cjc 1295 no dac 5mg & ipamorelin 5mg CJC-1295 + CJC-1295 No DAC 5mg +

The clinical trials on combining EpCAM targeting with other immunotherapies (such as checkpoint blockade) are ongoing

612 weeks: Noticeable evening of skin tone, lightening of stubborn dark spots for many users, improved skin clarity and reduced appearance of pigmentation when used consistently

Inject slowly and steadily for improved comfort and less post-injection leakage

10.1097/ACI.0b013e3282f3d913

Among its known binding partners are E3 ligases TRIM27 and RNF41, and the deubiquitinases USP7 and USP8, which it recruits to regulate the ubiquitination and stability of diverse targets (Tacer and Potts, 2017

Disadvantages are: raising potassium, lowering BP (dizzy on standing, dehydrated), reversibly raising liver tests (need to monitor every 3 months)